OpenLB
Open Library of Bioscience
Advanced Search
Journal of inflammation research
2025;18 381-403.

Kuiyangling Enema Alleviates Ulcerative Colitis Mice by Reducing Levels of Intestinal NETs and Promoting HuR/VDR Signaling.

Dong Zhang, Zeming Zhu, Zhangyou He, Siwei Duan, Qincheng Yi, Min Qiu, Xingzhen Dai, Guang Su, Kexin Li, Lin Xu, Donghou Liu, Yabin Wu, Yong Gao, Ruliu Li, Shaoju Guo
Author Information
  1. Dong Zhang: Gastroenterology Department, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong Province, 518000, People's Republic of China. ORCID
  2. Zeming Zhu: Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, 510000, People's Republic of China.
  3. Zhangyou He: Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, 510000, People's Republic of China.
  4. Siwei Duan: Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, 510000, People's Republic of China.
  5. Qincheng Yi: Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, 510000, People's Republic of China.
  6. Min Qiu: Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, 510000, People's Republic of China.
  7. Xingzhen Dai: Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, 510000, People's Republic of China.
  8. Guang Su: Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, 510000, People's Republic of China.
  9. Kexin Li: Gastroenterology Department, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong Province, 518000, People's Republic of China.
  10. Lin Xu: Gastroenterology Department, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong Province, 518000, People's Republic of China.
  11. Donghou Liu: Gastroenterology Department, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong Province, 518000, People's Republic of China.
  12. Yabin Wu: Gastroenterology Department, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong Province, 518000, People's Republic of China.
  13. Yong Gao: Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, 510000, People's Republic of China. ORCID
  14. Ruliu Li: Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, 510000, People's Republic of China.
  15. Shaoju Guo: Gastroenterology Department, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong Province, 518000, People's Republic of China.
PMID: 39802513 DOI: 10.2147/JIR.S492818

Abstract

Purpose: Kuiyangling is a traditional Chinese medicine formula used for the treatment of ulcerative colitis, but the specific mechanism remains unclear. Imbalance in NETs regulation is one of the important factors contributing to the onset of ulcerative colitis (UC). The HuR/VDR signaling pathway plays a significant role in restoring the intestinal mucosal barrier in UC. The aim of this study is to explore the mechanism of Kuiyangling in the treatment of ulcerative colitis.
Methods: A mouse model of ulcerative colitis using 3% DSS water was considered, and model, normal, Kuiyangling medium- (5 g��kg) and high-dose (10 g��kg), and mesalazine (50 mg��kg) groups were created. Measurements of colon length, spleen index, histopathological variances, subcellular structure observations, ROS content, and NET-related proteins (PAD4, MPO, citH3) were obtained through HE staining, electron microscopy, live imaging, and Western blotting assays. Immunohistochemistry and immunofluorescence analyses were conducted to assess the levels of HuR/VDR protein complex, ZO-1, Occludin, Claudin-7, and intestinal NETs. An ELISA kit was utilized to determine cytokine levels, LC-MS was performed to analyze the composition of Kuiyangling, and next-generation sequencing was conducted for detection of the intestinal mucosal transcriptome.
Results: Kuiyangling reduced DAI, splenic index, and ROS content; maintained mucosal structure; decreased inflammation; and increased colon length and body mass index. Western blotting indicated that Kuiyangling reduced PAD4,MPO, and citH3 levels. Kuiyangling decreased NETs and increased the expression levels of ZO-1, Occludin, and Claudin-7, as well as up-regulating HuR, VDR, and HuR/VDR proteins. Kuiyangling reduced IL-1��, IL-6, and TNF-�� levels while increasing TGF-��, IL-10, and IL-37 levels. Kuiyangling reduced inflammatory response proteins and elevated the levels of anti-inflammatory and intestinal barrier proteins, possibly inhibiting the TNF and oxidative phosphorylation signaling pathways.
Conclusion: Kuiyangling enema in treating ulcerative colitis in mice, associated with a reduction in intestinal NETs and enhancement of HuR-mediated intestinal barrier signaling pathways.

Keywords

Chinese medicine enema therapy inflammation neutrophil extracellular traps ulcerative colitis

References

  1. Am J Reprod Immunol. 2023 Mar;89(3):e13656 [PMID: 36409534]
  2. Cell Mol Gastroenterol Hepatol. 2021;12(1):321-333 [PMID: 33689803]
  3. Am J Pathol. 2023 Jun;193(6):656-668 [PMID: 36868465]
  4. Blood. 2019 May 16;133(20):2178-2185 [PMID: 30898862]
  5. Inflamm Bowel Dis. 2020 Jul 17;26(8):1131-1143 [PMID: 32232386]
  6. Mol Biol Cell. 2014 Nov 1;25(21):3308-18 [PMID: 25165135]
  7. EBioMedicine. 2021 Apr;66:103329 [PMID: 33862588]
  8. J Steroid Biochem Mol Biol. 2018 Jan;175:23-28 [PMID: 28025175]
  9. J Am Acad Dermatol. 2018 Oct;79(4):599-614 [PMID: 30241623]
  10. Cells. 2020 Apr 08;9(4): [PMID: 32276504]
  11. J Crohns Colitis. 2022 Feb 23;16(2):179-189 [PMID: 34635910]
  12. Gastroenterology. 2022 Apr;162(4):1147-1159.e4 [PMID: 34995526]
  13. Gastroenterology. 2022 Apr;162(5):1396-1408 [PMID: 35101421]
  14. Clin Med (Lond). 2021 Mar;21(2):135-139 [PMID: 33762374]
  15. J Crohns Colitis. 2020 Jun 19;14(5):694-709 [PMID: 31777929]
  16. Cold Spring Harb Perspect Biol. 2020 Jul 1;12(7): [PMID: 31767647]
  17. Nat Med. 2021 Nov;27(11):1970-1981 [PMID: 34675383]
  18. Front Immunol. 2021 Mar 30;12:622934 [PMID: 33859636]
  19. Sheng Li Xue Bao. 2020 Jun 25;72(3):325-335 [PMID: 32572430]
  20. Cell Cycle. 2019 Nov;18(21):2928-2938 [PMID: 31496351]
  21. Infect Immun. 2022 Feb 17;90(2):e0055121 [PMID: 34871043]
  22. Infect Immun. 2016 Mar 24;84(4):976-988 [PMID: 26787720]
  23. Mayo Clin Proc. 2019 Jul;94(7):1357-1373 [PMID: 31272578]
  24. Pharmacol Res. 2021 Sep;171:105779 [PMID: 34298111]
  25. Front Cell Dev Biol. 2023 Jan 05;10:1099038 [PMID: 36684420]
  26. Nat Commun. 2022 Jun 14;13(1):3432 [PMID: 35701435]
  27. Inflamm Bowel Dis. 2023 May 2;29(5):783-797 [PMID: 36617175]
  28. Am J Chin Med. 2022;50(7):1781-1798 [PMID: 35950375]
  29. Autoimmun Rev. 2020 Nov;19(11):102672 [PMID: 32942038]
  30. Gut. 2015 Jul;64(7):1082-94 [PMID: 25080448]
  31. Int J Mol Sci. 2020 Dec 31;22(1): [PMID: 33396382]
  32. Am J Physiol Cell Physiol. 2020 Jul 1;319(1):C208-C217 [PMID: 32432928]
  33. J Crohns Colitis. 2019 May 27;13(6):772-784 [PMID: 30715224]
  34. Nat Rev Immunol. 2018 Feb;18(2):134-147 [PMID: 28990587]
  35. Mol Cell Biol. 2017 Mar 17;37(7): [PMID: 28031329]
  36. J Leukoc Biol. 2021 Oct;110(4):797-808 [PMID: 33378572]
  37. Cell Mol Immunol. 2019 Jan;16(1):19-27 [PMID: 29572545]
  38. Dtsch Arztebl Int. 2020 Aug 17;117(33-34):564-574 [PMID: 33148393]
  39. Thromb Haemost. 2016 Apr;115(4):738-51 [PMID: 26660948]
  40. J Crohns Colitis. 2020 Feb 10;14(2):240-253 [PMID: 31325355]
  41. Front Pharmacol. 2022 Mar 07;13:844961 [PMID: 35321324]
  42. Iran J Allergy Asthma Immunol. 2018 Jun;17(3):208-220 [PMID: 29908538]
  43. Cell Death Discov. 2020 Apr 22;6:26 [PMID: 32351713]
  44. Front Pharmacol. 2021 Nov 24;12:747856 [PMID: 34899302]
  45. Biomolecules. 2019 Aug 14;9(8): [PMID: 31416173]
  46. Infect Immun. 2012 May;80(5):1891-9 [PMID: 22371374]
  47. Trends Mol Med. 2020 Nov;26(11):1034-1046 [PMID: 32620502]
  48. Nat Rev Dis Primers. 2020 Sep 10;6(1):74 [PMID: 32913180]
  49. Gastroenterology. 2019 Sep;157(3):731-743 [PMID: 31103627]
  50. Clin Rev Allergy Immunol. 2021 Oct;61(2):194-211 [PMID: 32740860]
  51. J Immunol. 2018 Jun 15;200(12):3950-3961 [PMID: 29712770]
  52. Front Biosci (Landmark Ed). 2023 Oct 25;28(10):262 [PMID: 37919092]
  53. Adv Drug Deliv Rev. 2022 May;184:114179 [PMID: 35248670]
  54. Nature. 2019 May;569(7755):236-240 [PMID: 31043745]
  55. Gastroenterol Clin North Am. 2020 Dec;49(4):643-654 [PMID: 33121686]
  56. Lancet Gastroenterol Hepatol. 2022 Feb;7(2):161-170 [PMID: 34856198]
  57. Cells. 2022 Mar 27;11(7): [PMID: 35406694]
  58. Am Fam Physician. 2022 Apr 1;105(4):406-411 [PMID: 35426646]
  59. J Ethnopharmacol. 2022 May 10;289:115084 [PMID: 35134488]
  60. Adv Drug Deliv Rev. 2022 Sep;188:114442 [PMID: 35817212]
  61. Nutrients. 2022 Mar 24;14(7): [PMID: 35405966]
Journal Article

Word Cloud

Created with Highcharts 10.0.0KuiyanglinglevelsulcerativecolitisintestinalNETsHuR/VDRproteinsreducedsignalingmucosalbarrierindexChinesemedicinetreatmentmechanismUCmodelg��kgcolonlengthstructureROScontentPAD4MPOcitH3WesternblottingconductedZO-1OccludinClaudin-7decreasedinflammationincreasedpathwaysenemaPurpose:traditionalformulaused forspecificremainsunclearImbalanceregulationoneimportantfactorscontributingonsetpathwayplayssignificantrolerestoringaimstudyexploreMethods:mouseusing3%DSSwaterconsiderednormalmedium-5high-dose10mesalazine50mg��kggroupscreatedMeasurementsspleenhistopathologicalvariancessubcellularobservationsNET-relatedobtainedHEstainingelectronmicroscopyliveimagingassaysImmunohistochemistryimmunofluorescenceanalysesassessproteincomplexELISAkitutilizeddeterminecytokineLC-MSperformedanalyzecompositionnext-generationsequencingdetectiontranscriptomeResults:DAIsplenicmaintainedbodymassindicatedexpressionwellup-regulatingHuRVDRIL-1��IL-6TNF-��increasingTGF-��IL-10IL-37inflammatoryresponseelevatedanti-inflammatorypossiblyinhibitingTNFoxidativephosphorylationConclusion:treatingmiceassociatedreductionenhancementHuR-mediatedEnemaAlleviatesUlcerativeColitisMiceReducingLevelsIntestinalPromotingSignalingtherapyneutrophilextracellulartraps

Similar Articles

Cited By